CASI Pharmaceuticals Statistics
Share Statistics
CASI Pharmaceuticals has 13.40M shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 13.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.83M |
| Failed to Deliver (FTD) Shares | 16 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 75.57K, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 75.57K |
| Short % of Shares Out | 0.56% |
| Short % of Float | 1.97% |
| Short Ratio (days to cover) | 2.36 |
Valuation Ratios
The PE ratio is -3.55 and the forward PE ratio is -2.63.
| PE Ratio | -3.55 |
| Forward PE | -2.63 |
| PS Ratio | 2.82 |
| Forward PS | 0.6 |
| PB Ratio | 3.96 |
| P/FCF Ratio | -4.31 |
| PEG Ratio | n/a |
Enterprise Valuation
CASI Pharmaceuticals Inc. has an Enterprise Value (EV) of 99.81M.
| EV / Earnings | -3.71 |
| EV / Sales | 2.95 |
| EV / EBITDA | -4.63 |
| EV / EBIT | -3.98 |
| EV / FCF | -4.49 |
Financial Position
The company has a current ratio of 3.55, with a Debt / Equity ratio of 0.78.
| Current Ratio | 3.55 |
| Quick Ratio | 2.6 |
| Debt / Equity | 0.78 |
| Total Debt / Capitalization | 43.88 |
| Cash Flow / Debt | -1.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.11% and return on capital (ROIC) is -55.07%.
| Return on Equity (ROE) | -1.11% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -55.07% |
| Revenue Per Employee | 192.49K |
| Profits Per Employee | -153.06K |
| Employee Count | 176 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 0.87 |
Taxes
| Income Tax | -81.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -49.76% in the last 52 weeks. The beta is 0.65, so CASI Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.65 |
| 52-Week Price Change | -49.76% |
| 50-Day Moving Average | 4.34 |
| 200-Day Moving Average | 4.7 |
| Relative Strength Index (RSI) | 43.2 |
| Average Volume (20 Days) | 45.12K |
Income Statement
In the last 12 months, CASI Pharmaceuticals had revenue of 33.88M and earned -26.94M in profits. Earnings per share was -2.02.
| Revenue | 33.88M |
| Gross Profit | 20.05M |
| Operating Income | -25.08M |
| Net Income | -26.94M |
| EBITDA | -21.54M |
| EBIT | -25.08M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has 17.08M in cash and 21.24M in debt, giving a net cash position of -4.16M.
| Cash & Cash Equivalents | 17.08M |
| Total Debt | 21.24M |
| Net Cash | -4.16M |
| Retained Earnings | -660.82M |
| Total Assets | 63.62M |
| Working Capital | 32.41M |
Cash Flow
In the last 12 months, operating cash flow was -19.97M and capital expenditures -2.24M, giving a free cash flow of -22.21M.
| Operating Cash Flow | -19.97M |
| Capital Expenditures | -2.24M |
| Free Cash Flow | -22.21M |
| FCF Per Share | -1.66 |
Margins
Gross margin is 5.92K%, with operating and profit margins of -7.40K% and -7.95K%.
| Gross Margin | 5.92K% |
| Operating Margin | -7.40K% |
| Pretax Margin | -7.76K% |
| Profit Margin | -7.95K% |
| EBITDA Margin | -63.58% |
| EBIT Margin | -74.03% |
| FCF Margin | -65.55% |
Dividends & Yields
CASI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -65.16% |
| FCF Yield | -53.46% |
Analyst Forecast
The average price target for CASI is $6, which is 93.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 93.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 2, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 2, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -15.24 |
| Piotroski F-Score | 1 |